Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBERTY EXTENSION: Relugolix combination therapy in uterine fibroids
NCT03412890Phase 3Completed
- Sponsor
- Myovant Sciences
- Start
- Oct 2017
- Primary completion
- Jan 2020
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 9
01
Overview
A Phase 3 trial of relugolix in Uterine Fibroids (UF), sponsored by Myovant Sciences. Started Oct 2017; status: completed.
02
Drugs
relugolix
03
Conditions
Uterine Fibroids (UF)
Beyond the preview
Go deeper on NCT03412890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03412890.